Hope4 HF

Title: HOPE4 HF – Health Outcomes Prospective Evaluation for Heart Failure with EF ≥ 40% (HOPE4HF)

Study Sponsor: CVRx

Principal Investigator: David S. Feldman, PhD, MD 

Study Synopsis: The purpose of this clinical investigation is to demonstrate the safety and efficacy of the Rheos Baroreflex Activation Therapy System in subjects with heart failure with preserved ejection fraction in a prospective, randomized trial. The CVRx Health Outcomes Prospective Evaluation for Heart Failure with EF ≥ 40% (HOPE4HF) trial is a prospective, randomized trial of approximately 540 subjects randomized at up to 70 US sites and up to 20 sites outside of the US.  

How do I qualify?  Be at least 21 years of age, have to have been hospitalized for heart failure within past 12 months and experience symptomatic heart failure. There are several tests and/or procedures that will be completed to determine if you qualify.

Status:  Open for enrollment

Who do I contact for more information? Holly MacDonald RN.CCRC